TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15197520
Drug: Daytime intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime intravenous desmopressin (2 microg)
Study: 15197520
Drug: Daytime oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime oral desmopressin (0.2 mg)
Study: 9569997
Drug: Avitriptan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitriptan 50 mg under fasting conditions
Study: 9569997
Drug: Avitriptan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitriptan 50 mg after a high-fat breakfast
Study: 3073524
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g four times daily for up to 12 weeks)
Study: 3073524
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g four times daily for up to 12 weeks)
Study: 28245243
Drug: Serelaxin intravenous
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin intravenous infusion (80 μg/kg/d for 60 min, then 30 μg/kg/d for 60 min)
Study: 28245243
Drug: Terlipressin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (single 2-mg i.v. bolus)
Study: 23509083
Drug: Homologous platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous platelet gel (PG)
Study: 9602198
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide 1 mg every 12 hours for 5 days, then 500 micrograms every 12 hours for a total of 6 weeks
Study: 2537699
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 5 mg benazepril hydrochloride
Study: 4909817
Drug: Carbenoxolone sodium
Normalized name: carbenoxolone sodium
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone sodium capsules (50 mg, four times a day for 12 weeks)
Study: 4909817
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (capsule identical in every respect except that it did not contain carbenoxolone)
Study: 26052147
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g Beta-Alanine (BA) + 34 g dextrose
Study: 26052147
Drug: Placebo (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (34 g dextrose)
Study: 23719347
Drug: Low birth
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low birth weight (2000-2499 g)
Study: 19536128
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg once daily)
Study: 16295054
Drug: Pulsating electrostatic
Normalized name: ABG Pulsator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsating electrostatic field (PESF) therapy, 30 min daily exposure, adjusted between 2 and 9 kV
Study: 15332347
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg/day upon awakening
Study: 15332347
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg/day at bedtime
Study: 15332347
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg/day at bedtime (polytherapy)
Study: 1402213
Drug: Indobufen (INB)
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (INB) 400 mg daily
Study: 1402213
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 900 mg daily plus dipyridamole (DP) 225 mg daily
Study: 29286989
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy-based stress management program for 10 weeks
Study: 26137881
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day) in rash subgroup
Study: 23811987
Drug: Desmopressin orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin orally disintegrating tablet (ODT)
Study: 10591433
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin
Study: 23811987
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin to desmopressin ODT
Study: 21692282
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus herbal medicine
Study: 11681532
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and 5-fluorouracil
Study: 9779028
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg every 12 h subcutaneously
Study: 9779028
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) as a continuous intravenous infusion
Study: 25359424
Drug: Oral T3
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral T3 treatment (20 μg per day for 3 months)
Study: 22819624
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg clonazepam
Study: 22819624
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg clonazepam
Study: 17547048
Drug: Regimen-1: albendazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-1: albendazole 800 mg/day twice daily for 3 consecutive days
Study: 17547048
Drug: Regimen-2: albendazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-2: albendazole 800 mg/day twice daily for 5 consecutive days
Study: 9405962
Drug: Tianeptine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (12.5 mg t.i.d)
Study: 8199696
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg/day) and Ursodeoxycholic acid (600 mg/day)
Study: 23816723
Drug: Control (neither
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (neither drug)
Study: 31173870
Drug: Yogliptin 2.5-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogliptin 2.5-600 mg
Study: 31173870
Drug: Yogliptin 25-400
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogliptin 25-400 mg
Study: 31173870
Drug: Yogliptin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogliptin 400 mg
Study: 17237134
Drug: Carvedilol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (up to 25 mg twice a day)
Study: 14963054
Drug: Low-soluble fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-soluble fiber diet (0.4 g added soluble fiber/2800 kcal)
Study: 14963054
Drug: Medium-soluble fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-soluble fiber diet (3 g added soluble fiber/2800 kcal)
Study: 14963054
Drug: High-soluble fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-soluble fiber diet (6 g added soluble fiber/2800 kcal)
Study: 8979210
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Coping Skills Therapy
Study: 8979210
Drug: Twelve-Step Facilitation
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve-Step Facilitation Therapy
Study: 8979210
Drug: 12-step facilitation
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step facilitation treatment
Study: 3662056
Drug: naloxone 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 0.08 mg IV every 2 min
Study: 3662056
Drug: nalbuphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 2.5 mg IV every 2 min
Study: 25541821
Drug: Azithromycin: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin: 500 mg once per day for 3 days + standard medical care
Study: 25541821
Drug: Azithromycin: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin: 500 mg once per day for 7 days, followed by 500 mg once per week for 12 weeks + standard medical care
Study: 15823180
Drug: Calf muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf muscle energy metabolism in COPD patients
Study: 15823180
Drug: Calf muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf muscle energy metabolism in control subjects
Study: 12435217
Drug: Isoflavone preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone preparations
Study: 7867177
Drug: 0.4 mg/h
Normalized name: nitroglycerin 0.4 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/h GTN skin patch
Study: 3969339
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL of ferrous sulfate (FeSO4) drops (about 3 mg of iron per kilogram per day) for 3 months
Study: 3969339
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL of ferrous sulfate (FeSO4) drops
Study: 28913896
Drug: Topical non-azole
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical non-azole solution applied to one paw
Study: 22124101
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) plus Bevacizumab (15 mg/kg) (CPB)
Study: 22124101
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) (CP)
Study: 18254223
Drug: Longidase (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longidase (3000 IU, 10 injections, once in 5 days)
Study: 12638810
Drug: Advance provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advance provision of oral contraceptives (20 clients)
Study: 12638810
Drug: Standard provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard provision of oral contraceptives (280 clients)
Study: 9430262
Drug: Multivitamin/mineral supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/mineral supplement (in a parallel trial)
Study: 8091822
Drug: Enoximone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.75 mg/kg i.v.)
Study: 8091822
Drug: Enoximone (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.075 mg/kg i.v.)
Study: 8091822
Drug: Enoximone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (oral administration over one week)
Study: 8091822
Drug: Gallopamil (Ca(++)-blocker)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (Ca(++)-blocker)
Study: 14747389
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg folic acid
Study: 29878267
Drug: 1.13 mg
Normalized name: B12/levomefolate calcium/B-6 2 mg-1.13 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.13 mg l-5-MTHF
Study: 24070102
Drug: Issued only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Issued only a prescription
Study: 21397769
Drug: Fenofibrate/pravastatin 160/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate/pravastatin 160/40 mg FDC
Study: 17301734
Drug: Tadalafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (10 mg)
Study: 14557148
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (n = 28)
Study: 11095435
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg androstenedione (ASD) three times daily
Study: 8623961
Drug: Ondansetron 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.075 mg/kg
Study: 1543677
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of terbinafine
Study: 1543677
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of terbinafine
Study: 1543677
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of terbinafine
Study: 1543677
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of terbinafine
Study: 3897535
Drug: Piroxicam 10-20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 10-20 mg once daily
Study: 3897535
Drug: Indomethacin 75-125
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75-125 mg in divided doses
Study: 31079275
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin mini-tablets (PedPRM; 2–5 mg)
Study: 19995670
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus bupropion
Study: 19995670
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus placebo
Study: 15517433
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (5000 mg per day)
Study: 7552480
Drug: Didanosine sachets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine sachets (250 mg or 167 mg twice daily for at least 1 month)
Study: 7552480
Drug: Didanosine chewable/dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine chewable/dispersible tablets (200 mg or 125 mg after conversion from sachets)
Study: 7552480
Drug: Low-dose ddI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ddI (sachets, 167 mg; tablets, 125 mg)
Study: 7552480
Drug: High-dose ddI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ddI (sachets, 250 mg; tablets, 200 mg)
Study: 6109568
Drug: Halazepam (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halazepam (80 to 160 mg)
Study: 6109568
Drug: Clorazepate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate (15 to 30 mg)
Study: 31714322
Drug: 0.2 mg/mL
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/mL oxycodone plus 0.1% ropivacaine
Study: 23382637
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 40% wt/vol barium sulfate suspension before 3 mealtimes, 60 mL 60% diatrizoate meglumine diluted in 250 mL water after supper, and 10 mg bisacodyl enteric‐coated tablets 1 h before oral administration of 2 L PEG‐4000 electrolyte solution (Study Group A)
Study: 23382637
Drug: Identical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical treatment to Study Group A, but bisacodyl was given 1 h after oral PEG‐4000 (Study Group B)
Study: 23382637
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group managed using the same strategy as Study Group A, but without administration of bisacodyl
Study: 19214123
Drug: Saquinavir/ritonavir (SQV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir/ritonavir (SQV/r) 1000 mg/100 mg twice a day
Study: 19214123
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice a day
Study: 17626759
Drug: Shenqi injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi injection after operation
Study: 17626759
Drug: No immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immune supportive treatment (Control)
Study: 11718454
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with beta-carotene (6 mg), vitamin E (30 mg), vitamin C (120 mg), selenium (100 microg), and zinc (20 mg) for 2 years
Study: 8483620
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (5 mg/kg twice daily for 10 days)
Study: 8483620
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (13.4 mg/kg three times daily for 10 days)
Study: 26505570
Drug: Ropivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (10 mL, 75 mg)
Study: 25391305
Drug: B-vitamin group
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin group (400 µg folic acid and 500 µg vitamin B12 daily)
Study: 12888775
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of encapsulated dried leaf
Study: 12888775
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of encapsulated dried leaf
Study: 12888775
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg of encapsulated dried leaf
Study: 22959103
Drug: L‐CRA (Laser-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐CRA (Laser-induced chorioretinal venous anastomosis)
Study: 19179968
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2b monotherapy (1.5 micro g/kg/wk for 48 weeks)
Study: 19179968
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (pegylated interferon alfa-2b + lamivudine 100 mg/d)
Study: 17401588
Drug: Non‐self‐tapping Ankylos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐self‐tapping Ankylos implants
Study: 17401588
Drug: Self‐tapping Camlog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐tapping Camlog implants
Study: 11219481
Drug: Extended-release clarithromycin
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release clarithromycin (two 500-mg tablets once daily for 7 days)
Study: 11219481
Drug: Amoxicillin/clavulanate (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (one 875-mg tablet twice daily for 10 days)
Study: 11219481
Drug: Extended-release clarithromycin
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release clarithromycin
Study: 8287747
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein level higher than 2.5 mg/dl (Group A)
Study: 8287747
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein level lower than 2.5 mg/dl (Group B)
Study: 27234409
Drug: Talactoferrin (TLf)
Normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talactoferrin (TLf) administered twice daily by gastric gavage from day 1-28 of life
Study: 16897910
Drug: Computer-administered survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered survey
Study: 12942855
Drug: Continuous trajectory
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous trajectory of psychotropic drug consumption (uninterrupted consumption during the 5-year follow-up)
Study: 12942855
Drug: Occasional trajectory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occasional trajectory of psychotropic drug consumption (interruption of consumption for at least 1 month)
Study: 8911887
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg) with grapefruit juice (250 ml)
Study: 8911887
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg) with water
Study: 6961737
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk (1.6 g/100 kcal)
Study: 6961737
Drug: Formula 1
Normalized name: Abena Man Formula 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula 1 (2.3 g/100 kcal)
Study: 6961737
Drug: Formula 2
Normalized name: Formula 21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula 2 (3.0 g/100 kcal)
Study: 31499415
Drug: sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil 25 mg three times daily
Study: 30646105
Drug: No stimulants
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stimulants
Study: 30646105
Drug: Long-term concurrent
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term concurrent stimulant-opioid use
Study: 24532143
Drug: Haloperidol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group, n = 59)
Study: 24532143
Drug: Haloperidol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group)
Study: 17236758
Drug: Calcitriol 0.25
Normalized name: CALCITRIOL 0.25MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.25 mcg b.i.d.
Study: 11960538
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n = 85) with tailored recommendations about optimizing dialysis prescriptions, expedited conversion of catheters to grafts/fistulas, and patient education.
Study: 8559862
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia with neutral phrases (color blue or yellow combined with objects ball or kite)
Study: 344084
Drug: Trancopal (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trancopal (two tablets at night for two weeks)
Study: 344084
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets at night for two weeks)
Study: 23819219
Drug: Ear-apex blood-letting
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear-apex blood-letting (5-6 blood drops/time, once daily for 3 times)
Study: 23819219
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (local application of hydrochloric levofloxacin and erycin ointment, plus local warm compress)
Study: 11378948
Drug: Forced air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced air warming therapy
Study: 9009975
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (stepped plan from 1 evening injection to multiple daily injections)